MeSH term
Frequency | Condition_Probility | Female | 301 | 0.0 |
Humans | 758 | 0.0 |
Pregnancy | 9 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Adolescent | 100 | 0.0 |
Adult | 261 | 0.0 |
Aged | 130 | 0.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
Male | 303 | 0.0 |
Membrane Proteins/genetics/*metabolism | 2 | 0.0 |
Middle Aged | 216 | 0.0 |
Neoplasm Proteins/genetics/metabolism | 3 | 2.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Prognosis | 26 | 0.0 |
RNA, Messenger/genetics | 6 | 0.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
Research Support, Non-U.S. Gov't | 377 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Survival Analysis | 9 | 0.0 |
Up-Regulation | 18 | 0.0 |
Carcinoma, Renal Cell/*genetics | 36 | 37.0 |
Endothelial Growth Factors/*genetics | 5 | 2.0 |
Kidney Neoplasms/*genetics | 40 | 19.0 |
Ligases/*genetics | 35 | 34.0 |
*Loss of Heterozygosity | 23 | 6.0 |
Lymphokines/*genetics | 5 | 2.0 |
*Tumor Suppressor Proteins | 270 | 20.0 |
*Ubiquitin-Protein Ligases | 261 | 48.0 |
Vascular Endothelial Growth Factor A | 34 | 1.0 |
Vascular Endothelial Growth Factors | 33 | 0.0 |
Comparative Study | 42 | 0.0 |
Hippel-Lindau Disease/complications/*pathology | 3 | 100.0 |
Adrenal Gland Neoplasms/genetics | 9 | 32.0 |
Child | 69 | 0.0 |
Diagnosis, Differential | 31 | 1.0 |
*Gene Deletion | 13 | 1.0 |
*Genes, Tumor Suppressor | 112 | 11.0 |
Germ-Line Mutation/*genetics | 11 | 7.0 |
Heterozygote Detection | 3 | 0.0 |
Hippel-Lindau Disease/*diagnosis/*genetics | 6 | 100.0 |
Phenotype | 54 | 0.0 |
Pheochromocytoma/diagnosis/genetics | 4 | 80.0 |
Mutation/*genetics | 8 | 0.0 |
Pedigree | 66 | 0.0 |
Proteins/*genetics | 61 | 3.0 |
Animals | 140 | 0.0 |
Base Sequence/genetics | 5 | 1.0 |
Cell Line | 46 | 0.0 |
Conserved Sequence | 4 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
Genes, Tumor Suppressor/*physiology | 18 | 16.0 |
Hela Cells | 19 | 0.0 |
Hippel-Lindau Disease/*genetics | 128 | 96.0 |
Molecular Sequence Data | 119 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 139 | 0.0 |
Transcription Factors/metabolism | 18 | 1.0 |
Tumor Cells, Cultured | 104 | 0.0 |
*Chromosomes, Human | 2 | 3.0 |
*Mutation | 52 | 1.0 |
Ovarian Neoplasms/*genetics/pathology | 2 | 2.0 |
Age of Onset | 15 | 1.0 |
Base Sequence | 90 | 0.0 |
DNA Primers | 21 | 0.0 |
Electron Transport Complex II | 3 | 11.0 |
Family | 5 | 1.0 |
Germ-Line Mutation | 25 | 6.0 |
Multienzyme Complexes/*genetics | 2 | 2.0 |
Oxidoreductases/*genetics | 2 | 2.0 |
Polymerase Chain Reaction | 88 | 0.0 |
Succinate Dehydrogenase/*genetics | 6 | 24.0 |
Blotting, Western | 23 | 0.0 |
Cell Hypoxia/physiology | 10 | 14.0 |
Cell Nucleus/*metabolism | 5 | 1.0 |
Cytoplasm/metabolism | 8 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Green Fluorescent Proteins | 8 | 0.0 |
Ligases/*metabolism | 13 | 14.0 |
Mice | 60 | 0.0 |
Oxygen/*metabolism | 6 | 4.0 |
Recombinant Fusion Proteins/genetics/metabolism | 5 | 0.0 |
Transcription Factors/genetics/*metabolism | 3 | 0.0 |
Ubiquitin/*metabolism | 5 | 2.0 |
Prospective Studies | 6 | 0.0 |
Risk Factors | 17 | 0.0 |
Blotting, Northern | 18 | 0.0 |
Carcinoma, Renal Cell/genetics | 20 | 57.0 |
Cyclin D1/*genetics | 2 | 3.0 |
Gene Expression Profiling | 7 | 0.0 |
Gene Expression Regulation, Neoplastic | 31 | 1.0 |
Kidney Neoplasms/genetics | 18 | 25.0 |
Oligonucleotide Array Sequence Analysis | 7 | 0.0 |
Oxygen/pharmacology | 3 | 7.0 |
Transfection | 53 | 0.0 |
Binding Sites | 16 | 0.0 |
Carcinoma, Renal Cell/genetics/*metabolism/pathology | 5 | 50.0 |
Genes, Tumor Suppressor | 69 | 8.0 |
Immunoenzyme Techniques | 11 | 0.0 |
Kidney Neoplasms/genetics/*metabolism/pathology | 5 | 38.0 |
Luciferases/metabolism | 3 | 0.0 |
Luminescent Proteins/metabolism | 5 | 1.0 |
Mice, SCID | 3 | 0.0 |
Monosaccharide Transport Proteins/metabolism | 5 | 12.0 |
Plasmids | 4 | 0.0 |
Recombinant Fusion Proteins | 3 | 0.0 |
Transcription Factors/*metabolism | 15 | 0.0 |
Transcription, Genetic | 27 | 0.0 |
Ubiquitin-Protein Ligases | 8 | 3.0 |
Carcinoma, Renal Cell/*genetics/metabolism/pathology | 6 | 50.0 |
Down-Regulation | 15 | 0.0 |
Kidney Neoplasms/*genetics/metabolism/pathology | 6 | 46.0 |
Ligases/*physiology | 2 | 20.0 |
Mice, Nude | 15 | 0.0 |
Mutation | 96 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Fluorescein Angiography | 14 | 12.0 |
Fundus Oculi | 6 | 6.0 |
Hemangioblastoma/*complications/diagnosis | 2 | 100.0 |
Hippel-Lindau Disease/*complications/*diagnosis/genetics | 2 | 100.0 |
Time Factors | 21 | 0.0 |
Hemangioblastoma/*complications/pathology | 2 | 100.0 |
Hippel-Lindau Disease/*complications/pathology | 3 | 100.0 |
Hyperparathyroidism/*complications | 2 | 50.0 |
Carcinoma, Renal Cell/*genetics/metabolism | 6 | 40.0 |
CpG Islands/genetics | 5 | 3.0 |
Immunohistochemistry | 45 | 0.0 |
Kidney Neoplasms/*genetics/metabolism | 7 | 25.0 |
Loss of Heterozygosity/genetics | 7 | 5.0 |
Methylation | 5 | 0.0 |
English Abstract | 58 | 0.0 |
Hippel-Lindau Disease/*complications | 29 | 100.0 |
Paraganglioma/complications | 2 | 100.0 |
Cysteine Endopeptidases/metabolism | 6 | 2.0 |
Hydrolysis | 6 | 0.0 |
Multienzyme Complexes/metabolism | 6 | 3.0 |
Proteasome Endopeptidase Complex | 8 | 1.0 |
Amino Acid Sequence | 60 | 0.0 |
Anoxia/metabolism | 4 | 10.0 |
Crystallography, X-Ray | 3 | 0.0 |
Hydrogen Bonding | 3 | 1.0 |
Hydroxylation | 8 | 2.0 |
Kinetics | 8 | 0.0 |
Models, Molecular | 12 | 0.0 |
Protein Binding | 27 | 0.0 |
Protein Conformation | 8 | 0.0 |
Sequence Alignment | 9 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Substrate Specificity | 3 | 0.0 |
Transcription Factors/*chemistry/*metabolism | 3 | 7.0 |
Adrenal Gland Neoplasms/*surgery | 3 | 75.0 |
Adrenalectomy/*methods | 3 | 100.0 |
Pheochromocytoma/*surgery | 2 | 66.0 |
Retrospective Studies | 35 | 1.0 |
Peptide Synthases/*metabolism | 3 | 9.0 |
Recombinant Proteins/metabolism | 11 | 0.0 |
Spodoptera | 2 | 0.0 |
Clinical Trials | 4 | 0.0 |
Hippel-Lindau Disease/genetics | 35 | 83.0 |
Neoplasm Staging | 19 | 0.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors | 4 | 9.0 |
Tumor Suppressor Proteins/genetics | 11 | 16.0 |
Ubiquitin-Protein Ligases/genetics | 9 | 47.0 |
Tumor Suppressor Proteins/*genetics | 19 | 14.0 |
Ubiquitin-Protein Ligases/*genetics | 18 | 51.0 |
Ligases/genetics/*physiology | 3 | 42.0 |
3T3 Cells | 3 | 0.0 |
COS Cells | 11 | 0.0 |
Protein Structure, Tertiary | 15 | 0.0 |
*Signal Transduction | 5 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Carcinoma, Renal Cell/epidemiology/*genetics | 2 | 66.0 |
*Epidemiology, Molecular | 2 | 11.0 |
Kidney Neoplasms/epidemiology/*genetics | 3 | 75.0 |
Aged, 80 and over | 31 | 0.0 |
Child, Preschool | 28 | 0.0 |
Cohort Studies | 4 | 0.0 |
*Drosophila Proteins | 14 | 1.0 |
*Germ-Line Mutation | 24 | 5.0 |
Heterozygote | 37 | 1.0 |
Multiple Endocrine Neoplasia Type 2a/genetics | 7 | 23.0 |
Mutation, Missense | 16 | 2.0 |
Pheochromocytoma/*genetics | 26 | 63.0 |
Proto-Oncogene Proteins/*genetics | 7 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 8 | 2.0 |
Carcinoma, Renal Cell/*genetics/pathology | 19 | 54.0 |
Chromosomes, Human, Pair 3/*genetics | 19 | 9.0 |
DNA Mutational Analysis | 71 | 1.0 |
DNA, Neoplasm/chemistry/genetics | 4 | 3.0 |
Family Health | 10 | 0.0 |
Karyotyping | 14 | 0.0 |
Kidney Neoplasms/*genetics/pathology | 24 | 32.0 |
Ligases/genetics | 14 | 37.0 |
Loss of Heterozygosity | 33 | 4.0 |
Microsatellite Repeats | 16 | 1.0 |
Point Mutation | 22 | 1.0 |
*Translocation, Genetic | 4 | 0.0 |
Hippel-Lindau Disease/*complications/*genetics | 3 | 100.0 |
In Situ Hybridization, Fluorescence | 17 | 0.0 |
Magnetic Resonance Imaging | 43 | 4.0 |
*Amino Acid Substitution | 2 | 2.0 |
Codon/genetics | 2 | 0.0 |
Hippel-Lindau Disease/diagnosis/*genetics | 16 | 94.0 |
Hypertension/etiology | 3 | 6.0 |
*Mutation, Missense | 6 | 1.0 |
Paraganglioma, Extra-Adrenal/*genetics | 3 | 42.0 |
*Point Mutation | 9 | 0.0 |
Chromosomes, Human, Pair 3 | 31 | 15.0 |
Erythropoietin/blood | 4 | 6.0 |
Ligases/*genetics/physiology | 2 | 66.0 |
Linkage (Genetics) | 21 | 0.0 |
Receptors, Growth Factor/*antagonists & inhibitors | 3 | 17.0 |
Receptors, Vascular Endothelial Growth Factor | 7 | 1.0 |
Ligases/*genetics/metabolism | 4 | 25.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Tomography, X-Ray Computed | 33 | 4.0 |
*DNA Methylation | 25 | 3.0 |
DNA, Neoplasm/metabolism | 2 | 1.0 |
Fluorescent Antibody Technique, Indirect | 6 | 0.0 |
*Gene Expression Regulation, Neoplastic | 17 | 1.0 |
Gene Silencing | 8 | 2.0 |
Infant | 10 | 0.0 |
Ligases/genetics/metabolism | 2 | 8.0 |
*Promoter Regions (Genetics) | 7 | 0.0 |
RNA, Messenger/metabolism | 15 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 14 | 0.0 |
Carcinoma, Renal Cell/*pathology | 2 | 12.0 |
Kidney Neoplasms/*pathology | 3 | 9.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Transcription Factors/*genetics | 5 | 0.0 |
Translocation, Genetic | 8 | 1.0 |
Cerebellar Neoplasms/*genetics | 8 | 42.0 |
Chromosome Aberrations | 5 | 0.0 |
DNA, Neoplasm/*genetics | 7 | 3.0 |
Exons/genetics | 12 | 0.0 |
Hemangioblastoma/*genetics | 8 | 100.0 |
Sequence Deletion/*genetics | 3 | 2.0 |
Deferoxamine/pharmacology | 4 | 9.0 |
*Trans-Activation (Genetics) | 3 | 0.0 |
*Transcription Factors | 21 | 1.0 |
Cell Transformation, Neoplastic/genetics | 8 | 2.0 |
Hippel-Lindau Disease/complications/*genetics | 14 | 100.0 |
Pancreatic Neoplasms/*genetics | 5 | 5.0 |
Blotting, Southern | 15 | 0.0 |
Carcinoma, Renal Cell/*genetics/*pathology | 3 | 75.0 |
DNA Methylation | 17 | 2.0 |
DNA, Neoplasm/genetics | 19 | 2.0 |
Kidney Neoplasms/*genetics/*pathology | 3 | 42.0 |
Mutation/genetics | 8 | 0.0 |
Hippel-Lindau Disease/complications/*genetics/pathology | 3 | 100.0 |
Proteins/genetics | 32 | 4.0 |
Repressor Proteins/genetics | 3 | 2.0 |
Adenocarcinoma/*genetics | 4 | 2.0 |
DNA Primers/chemistry | 7 | 0.0 |
Gene Deletion | 30 | 1.0 |
Genes, ras/*genetics | 2 | 2.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Adrenal Gland Neoplasms/diagnosis/*genetics | 2 | 100.0 |
Genetic Screening | 14 | 1.0 |
Paraganglioma/genetics | 4 | 66.0 |
Pheochromocytoma/diagnosis/*genetics | 2 | 100.0 |
Angiogenesis Inhibitors/therapeutic use | 2 | 6.0 |
Hippel-Lindau Disease/diagnosis/*genetics/therapy | 2 | 100.0 |
Self-Help Groups | 2 | 18.0 |
Transcription Factors/genetics | 7 | 0.0 |
Breast Neoplasms/*genetics/pathology | 4 | 1.0 |
Disease Progression | 12 | 0.0 |
*Gene Expression Profiling | 4 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Multigene Family | 3 | 0.0 |
*Genes, BRCA1 | 2 | 0.0 |
Carcinogens | 4 | 5.0 |
Ligases/genetics/*metabolism | 5 | 10.0 |
Rats | 35 | 0.0 |
Rats, Inbred F344 | 5 | 1.0 |
Cell Cycle Proteins/metabolism | 4 | 1.0 |
*Cullin Proteins | 11 | 17.0 |
Macromolecular Substances | 9 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Protein Folding | 4 | 0.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 2 | 2.0 |
Carcinoma, Squamous Cell/*genetics | 8 | 4.0 |
Lung Neoplasms/*genetics | 5 | 2.0 |
*Alleles | 8 | 0.0 |
Hemangioblastoma/genetics | 9 | 100.0 |
Models, Genetic | 12 | 0.0 |
Point Mutation/*genetics | 7 | 2.0 |
Polymorphism, Single-Stranded Conformational | 59 | 2.0 |
Adrenal Gland Neoplasms/*genetics | 17 | 56.0 |
*Chromosome Deletion | 21 | 2.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
DNA, Neoplasm/analysis | 17 | 2.0 |
Multiple Endocrine Neoplasia/genetics | 2 | 15.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Syndrome | 10 | 0.0 |
Keratin/analysis | 2 | 0.0 |
Stromal Cells/chemistry/pathology | 2 | 9.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Adrenalectomy | 6 | 12.0 |
Laparoscopy | 3 | 8.0 |
Gene Library | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 5 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Genotype | 39 | 0.0 |
Amino Acid Substitution | 5 | 0.0 |
Cell Hypoxia/*physiology | 2 | 3.0 |
Recombinant Fusion Proteins/metabolism | 7 | 0.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
DNA, Neoplasm/analysis/genetics | 5 | 5.0 |
Multiple Endocrine Neoplasia Type 2a/*genetics | 3 | 11.0 |
Adrenal Gland Neoplasms/genetics/pathology | 2 | 40.0 |
*Chromosome Aberrations | 6 | 1.0 |
Chromosome Mapping | 37 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, Knockout | 7 | 0.0 |
Pheochromocytoma/genetics/pathology | 4 | 80.0 |
Infant, Newborn | 7 | 0.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
Carcinoma, Hepatocellular/genetics | 2 | 7.0 |
CpG Islands/*genetics | 3 | 3.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Liver Neoplasms/genetics | 2 | 9.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Promoter Regions (Genetics) | 17 | 0.0 |
Sex Factors | 4 | 0.0 |
Tumor Suppressor Proteins/metabolism | 2 | 1.0 |
*Acid Anhydride Hydrolases | 12 | 5.0 |
*Chromosomes, Human, Pair 3 | 49 | 13.0 |
Neoplasm Proteins/genetics | 10 | 2.0 |
Polymerase Chain Reaction/methods | 14 | 1.0 |
Analysis of Variance | 2 | 0.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Ki-67 Antigen/analysis | 3 | 1.0 |
Neovascularization, Pathologic | 6 | 1.0 |
Sequence Analysis, DNA | 18 | 0.0 |
Survival Rate | 10 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Alleles | 34 | 0.0 |
Chromosome Deletion | 10 | 1.0 |
Frameshift Mutation | 6 | 1.0 |
Adrenal Gland Neoplasms/*etiology | 2 | 100.0 |
Neoplasms, Multiple Primary/*etiology | 2 | 66.0 |
Pheochromocytoma/*etiology | 2 | 100.0 |
Ubiquitin/metabolism | 3 | 1.0 |
Vascular Endothelial Growth Factor Receptor-1 | 2 | 0.0 |
*Antigens, Neoplasm | 2 | 1.0 |
Neurofibromatosis 2/genetics | 2 | 22.0 |
Molecular Biology | 9 | 3.0 |
Bladder Neoplasms/genetics | 2 | 16.0 |
Cadherins/genetics | 4 | 7.0 |
Genetic Screening/methods | 6 | 4.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 2 | 7.0 |
Prostatic Neoplasms/genetics | 2 | 4.0 |
Urogenital Neoplasms/*genetics | 2 | 100.0 |
Adenocarcinoma/*genetics/pathology | 3 | 3.0 |
*Cell Hypoxia | 5 | 7.0 |
Cobalt/pharmacology | 4 | 8.0 |
DNA-Binding Proteins/*metabolism | 14 | 0.0 |
Nuclear Proteins/*metabolism | 15 | 2.0 |
DNA, Complementary/metabolism | 7 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Immunoblotting | 7 | 0.0 |
Plasmids/metabolism | 8 | 0.0 |
Precipitin Tests | 9 | 0.0 |
Sequence Homology, Amino Acid | 17 | 0.0 |
Two-Hybrid System Techniques | 3 | 0.0 |
Age Factors | 8 | 0.0 |
Hippel-Lindau Disease/*complications/diagnosis | 5 | 100.0 |
Cell Hypoxia | 10 | 6.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Helix-Loop-Helix Motifs | 2 | 0.0 |
Nuclear Proteins/*genetics/metabolism | 3 | 2.0 |
Trans-Activators/metabolism | 3 | 0.0 |
Transcription Factors/*genetics/metabolism | 3 | 0.0 |
*Endolymphatic Sac/pathology/radiography | 2 | 100.0 |
Hippel-Lindau Disease/diagnosis/*genetics/pathology | 2 | 100.0 |
Cerebellum/pathology | 4 | 13.0 |
Genes, Dominant | 6 | 0.0 |
Adrenal Gland Neoplasms/diagnosis/genetics | 3 | 100.0 |
Hippel-Lindau Disease/classification/diagnosis/*genetics | 2 | 100.0 |
Hippel-Lindau Disease/complications/metabolism/*pathology | 2 | 100.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Treatment Outcome | 14 | 0.0 |
Tumor Markers, Biological/metabolism | 5 | 1.0 |
Incidence | 9 | 0.0 |
Databases, Factual | 2 | 0.0 |
Neoplasms/genetics | 5 | 4.0 |
Central Nervous System Neoplasms/*genetics/pathology | 2 | 20.0 |
Hemangioblastoma/*genetics/pathology | 3 | 100.0 |
Cells, Cultured | 19 | 0.0 |
Fungal Proteins/metabolism | 3 | 1.0 |
Gene Expression Regulation | 10 | 0.0 |
In Vitro | 2 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 8 | 2.0 |
Oxygen/metabolism | 9 | 4.0 |
Repressor Proteins/genetics/*metabolism | 2 | 1.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 6 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Trans-Activation (Genetics) | 7 | 0.0 |
Carcinoma, Renal Cell/genetics/metabolism | 4 | 57.0 |
Endothelial Growth Factors/*biosynthesis/genetics | 5 | 4.0 |
Kidney Neoplasms/genetics/metabolism | 2 | 16.0 |
*Ligases | 166 | 86.0 |
Lymphokines/*biosynthesis/genetics | 4 | 3.0 |
Trans-Activators/*biosynthesis/genetics | 3 | 10.0 |
Ubiquitins/metabolism | 10 | 7.0 |
Adenocarcinoma, Clear Cell/*genetics/pathology | 2 | 33.0 |
*Gene Silencing | 4 | 2.0 |
Neoplasm Proteins/*genetics | 3 | 0.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
*Chromosomes, Human, Pair 17 | 3 | 0.0 |
*Chromosomes, Human, Pair 9 | 2 | 0.0 |
Protein p16/genetics | 5 | 5.0 |
Protein p53/genetics | 3 | 1.0 |
Age Distribution | 2 | 0.0 |
Hippel-Lindau Disease/*complications/epidemiology/pathology | 2 | 100.0 |
Laser Coagulation | 2 | 12.0 |
Case-Control Studies | 4 | 0.0 |
Paraffin Embedding | 2 | 0.0 |
Tumor Markers, Biological | 7 | 1.0 |
Combined Modality Therapy | 4 | 0.0 |
Hippel-Lindau Disease/complications | 6 | 100.0 |
CHO Cells | 2 | 0.0 |
Cell Fusion | 4 | 1.0 |
Clone Cells | 2 | 0.0 |
DNA | 4 | 0.0 |
DNA-Binding Proteins/*physiology | 3 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Genetic Complementation Test | 3 | 0.0 |
Hamsters | 2 | 0.0 |
Genes, Tumor Suppressor/genetics/*physiology | 3 | 75.0 |
Hemangioblastoma/*genetics/pathology/surgery | 2 | 100.0 |
Hippel-Lindau Disease/*genetics/pathology/surgery | 3 | 100.0 |
Mutation, Missense/genetics | 4 | 2.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 12 | 0.0 |
Cell Nucleus/metabolism | 10 | 0.0 |
CpG Islands | 7 | 2.0 |
Exons | 21 | 0.0 |
Introns | 6 | 0.0 |
Polymorphism, Genetic | 17 | 0.0 |
Carrier Proteins/*genetics | 4 | 0.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
Nuclear Proteins/genetics | 3 | 1.0 |
Proteins/*metabolism | 10 | 1.0 |
SKP Cullin F-Box Protein Ligases | 3 | 7.0 |
Variation (Genetics) | 6 | 0.0 |
Chromosomes, Human, Pair 6 | 2 | 1.0 |
Chromosomes, Human, Pair 9 | 4 | 2.0 |
Pheochromocytoma/genetics | 10 | 40.0 |
Cysteine Endopeptidases | 2 | 4.0 |
*Hippel-Lindau Disease | 2 | 100.0 |
Carcinoma, Renal Cell/pathology | 3 | 30.0 |
Kidney Neoplasms/pathology | 3 | 25.0 |
Hippel-Lindau Disease/*complications/diagnosis/*genetics | 2 | 100.0 |
Cell Division/drug effects | 4 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
*Neoplasm Proteins | 8 | 1.0 |
Neoplasm Transplantation | 6 | 0.0 |
Neovascularization, Pathologic/genetics | 4 | 12.0 |
Gene Frequency | 7 | 0.0 |
Polymorphism, Restriction Fragment Length | 22 | 0.0 |
Cercopithecus aethiops | 5 | 0.0 |
Protein Binding/drug effects | 3 | 0.0 |
Proteins/genetics/*metabolism | 13 | 2.0 |
Deoxyribonuclease HpaII/metabolism | 2 | 15.0 |
Angiomatosis/genetics | 2 | 100.0 |
Penetrance | 2 | 1.0 |
Follow-Up Studies | 24 | 0.0 |
Risk Assessment | 3 | 0.0 |
*Hippel-Lindau Disease/diagnosis/genetics/therapy | 2 | 100.0 |
Cell Hypoxia/genetics | 5 | 29.0 |
Carcinoma, Renal Cell/metabolism/pathology | 2 | 50.0 |
Cell Communication | 3 | 1.0 |
Cell Division | 14 | 0.0 |
Proteins/chemistry/genetics/*metabolism | 4 | 4.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Genes, Tumor Suppressor/*genetics | 38 | 12.0 |
Nucleic Acid Denaturation | 3 | 3.0 |
RNA Splice Sites/genetics | 2 | 1.0 |
Reproducibility of Results | 6 | 0.0 |
Temperature | 5 | 0.0 |
Carcinoma/*genetics | 3 | 2.0 |
*Cell Cycle Proteins | 6 | 0.0 |
Adenocarcinoma, Clear Cell/genetics/pathology | 2 | 40.0 |
Carcinoma, Papillary/genetics/pathology | 2 | 33.0 |
Chromosomes, Human, Pair 3/genetics | 18 | 13.0 |
Hippel-Lindau Disease/complications/diagnosis/*genetics | 5 | 100.0 |
Neoplasm Invasiveness | 4 | 0.0 |
Patient Care Team | 2 | 11.0 |
Postoperative Complications/diagnosis | 2 | 20.0 |
Reoperation | 3 | 2.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Genes, Reporter | 5 | 0.0 |
Ubiquitin-Protein Ligases/metabolism | 2 | 4.0 |
Cell Adhesion | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Restriction Mapping | 7 | 0.0 |
Cloning, Molecular | 20 | 0.0 |
Insects | 2 | 1.0 |
Ligases/metabolism | 2 | 3.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Transcription Factors/*chemistry/metabolism | 4 | 8.0 |
Kidney Neoplasms/genetics/metabolism/pathology | 3 | 42.0 |
Protein Biosynthesis | 9 | 0.0 |
Proteins/genetics/*physiology | 10 | 7.0 |
DNA-Binding Proteins/genetics/*metabolism | 6 | 0.0 |
*Genetic Screening | 4 | 2.0 |
Japan | 9 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Genes, Tumor Suppressor/genetics | 25 | 15.0 |
Loss of Heterozygosity/*genetics | 5 | 5.0 |
Adrenal Gland Neoplasms/complications/genetics | 2 | 100.0 |
*Down-Regulation | 4 | 1.0 |
Neoplasms/*genetics | 9 | 3.0 |
Pheochromocytoma/complications/genetics | 3 | 100.0 |
Proteins/genetics/metabolism/*physiology | 2 | 5.0 |
Disease Models, Animal | 6 | 0.0 |
Cell Line, Tumor | 12 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Disease Susceptibility | 3 | 0.0 |
Kidney Neoplasms/genetics/surgery | 2 | 66.0 |
Nephrectomy | 7 | 8.0 |
Endothelial Growth Factors/*metabolism | 2 | 0.0 |
Hippel-Lindau Disease/genetics/*metabolism/pathology | 2 | 100.0 |
Lymphokines/*metabolism | 2 | 0.0 |
Protein p53/*metabolism | 3 | 0.0 |
Nerve Tissue Proteins/genetics | 2 | 0.0 |
Neurofibromatosis 1/genetics | 3 | 10.0 |
Proto-Oncogene Proteins/genetics | 8 | 1.0 |
Receptor Protein-Tyrosine Kinases/genetics | 10 | 6.0 |
Adenocarcinoma, Clear Cell/genetics/metabolism/pathology | 2 | 33.0 |
Kidney/metabolism | 5 | 1.0 |
Carbonic Anhydrases/genetics | 3 | 33.0 |
Carcinoma, Renal Cell/genetics/*metabolism | 5 | 45.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Chromosome Aberrations/genetics | 4 | 3.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Carcinoma, Renal Cell/genetics/*pathology | 3 | 50.0 |
Kidney Neoplasms/genetics/*pathology | 3 | 25.0 |
Ligases/metabolism/*physiology | 2 | 33.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 4 | 0.0 |
Leukemia/genetics | 2 | 4.0 |
Mutagenesis | 2 | 0.0 |
Phosphorylation | 6 | 0.0 |
Ubiquitins/*metabolism | 6 | 3.0 |
Hippel-Lindau Disease/*diagnosis | 2 | 100.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Nuclear Localization Signal | 2 | 2.0 |
Brain/pathology | 4 | 1.0 |
Cerebellar Neoplasms/diagnosis/surgery | 2 | 100.0 |
Hemangioblastoma/diagnosis/surgery | 2 | 100.0 |
Spinal Cord/pathology | 5 | 6.0 |
Amino Acid Substitution/*genetics | 2 | 3.0 |
Arginine/genetics | 2 | 1.0 |
Genetic Predisposition to Disease/genetics | 4 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Adenocarcinoma, Clear Cell/genetics | 4 | 30.0 |
Protein Isoforms | 2 | 0.0 |
Kidney Neoplasms/metabolism | 4 | 20.0 |
*Protein Biosynthesis | 7 | 1.0 |
Cell Differentiation | 4 | 0.0 |
Models, Biological | 5 | 0.0 |
*Anesthesia, Epidural | 2 | 18.0 |
Neoplasm Recurrence, Local/surgery | 2 | 50.0 |
Salvage Therapy | 2 | 2.0 |
Adenoviridae/genetics | 2 | 0.0 |
*Gene Therapy | 3 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Catecholamines/blood/urine | 2 | 100.0 |
Polycythemia/*genetics | 2 | 18.0 |
Retinal Neoplasms/genetics | 2 | 66.0 |
Proteins/*genetics/metabolism | 4 | 1.0 |
Bayes Theorem | 2 | 3.0 |
Prevalence | 7 | 0.0 |
Probability | 2 | 0.0 |
Retinal Neoplasms/*complications/pathology | 2 | 100.0 |
Mice, Mutant Strains | 2 | 0.0 |
Carcinoma/genetics | 2 | 6.0 |
Chromosome Painting | 2 | 4.0 |
DNA/metabolism | 3 | 0.0 |
Hybrid Cells | 5 | 0.0 |
Neoplasms, Experimental | 2 | 5.0 |
*Anoxia | 2 | 7.0 |
Endothelial Growth Factors/metabolism | 4 | 2.0 |
In Situ Hybridization | 11 | 0.0 |
Lymphokines/metabolism | 4 | 1.0 |
RNA/metabolism | 3 | 0.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Signal Transduction | 5 | 0.0 |
Radiosurgery | 2 | 40.0 |
DNA/analysis | 5 | 0.0 |
Hippel-Lindau Disease/complications/*diagnosis/genetics | 3 | 100.0 |
Cell Transformation, Neoplastic/genetics/pathology | 2 | 9.0 |
Kidney/pathology | 7 | 4.0 |
Chromosomes, Human, Pair 10/genetics | 2 | 2.0 |
Pancreatic Neoplasms/*genetics/pathology | 2 | 5.0 |
Chromosomes, Human, Pair 1/genetics | 3 | 1.0 |
DNA/genetics/isolation & purification | 3 | 1.0 |
Genes, p53/genetics | 4 | 1.0 |
Microtubule-Associated Proteins/metabolism | 3 | 2.0 |
Proteins/*genetics/physiology | 4 | 5.0 |
Neoplasm Recurrence, Local | 6 | 1.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
Phylogeny | 2 | 0.0 |
Endothelial Growth Factors/biosynthesis/genetics | 3 | 12.0 |
Lymphokines/biosynthesis/genetics | 3 | 10.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Multiple Endocrine Neoplasia Type 2a/complications | 2 | 100.0 |
Pheochromocytoma/complications/*surgery | 2 | 100.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Biopsy | 4 | 0.0 |
Hippel-Lindau Disease/*complications/genetics | 7 | 100.0 |
Oncogenes | 2 | 0.0 |
Organ Specificity | 4 | 0.0 |
Sequence Deletion | 9 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Microsatellite Repeats/genetics | 5 | 1.0 |
Promoter Regions (Genetics)/genetics | 5 | 0.0 |
Proto-Oncogene Protein c-met/genetics | 3 | 16.0 |
Gene Expression | 8 | 0.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
*Endolymphatic Sac | 3 | 100.0 |
Molecular Biology/methods | 2 | 7.0 |
Risk | 4 | 0.0 |
Drosophila | 2 | 0.0 |
Adrenal Gland Neoplasms/*genetics/pathology | 2 | 28.0 |
Genetic Markers | 28 | 0.0 |
Pheochromocytoma/*genetics/pathology | 2 | 50.0 |
Retinal Neoplasms/*genetics/pathology | 2 | 40.0 |
Stromal Cells/metabolism/pathology | 2 | 4.0 |
Genetic Predisposition to Disease | 11 | 0.0 |
*Proto-Oncogene Proteins | 3 | 0.0 |
Carcinoma, Renal Cell/*genetics/pathology/secondary | 2 | 100.0 |
Neoplasms, Multiple Primary/*genetics/pathology | 2 | 20.0 |
Adenocarcinoma, Clear Cell/*genetics | 7 | 87.0 |
*Hippel-Lindau Disease/diagnosis/genetics | 2 | 100.0 |
Proteins/genetics/physiology | 5 | 8.0 |
Cell Line, Transformed | 5 | 0.0 |
Protein Processing, Post-Translational | 5 | 0.0 |
Cell Extracts | 2 | 1.0 |
Proteins/*chemistry/genetics/*metabolism | 2 | 7.0 |
Carcinogenicity Tests | 2 | 2.0 |
Species Specificity | 2 | 0.0 |
Visual Acuity | 4 | 2.0 |
Genes, Tumor Suppressor/physiology | 2 | 4.0 |
Transduction, Genetic | 2 | 0.0 |
Epithelial Cells/cytology/metabolism | 2 | 3.0 |
Mitochondria/*metabolism | 3 | 1.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Proteins/*genetics/*metabolism | 2 | 2.0 |
Carcinoma, Renal Cell/genetics/pathology | 6 | 66.0 |
Hemangioblastoma/genetics/pathology | 2 | 100.0 |
Hippel-Lindau Disease/*genetics/pathology | 6 | 100.0 |
Netherlands | 3 | 1.0 |
*Sequence Deletion | 7 | 1.0 |
Cell Cycle Proteins/*genetics | 3 | 1.0 |
Chromosomes, Human, Pair 7 | 3 | 1.0 |
Germ-Line Mutation/genetics | 4 | 5.0 |
Transforming Growth Factor alpha/genetics | 2 | 7.0 |
Neoplasm Metastasis | 6 | 0.0 |
Nephrectomy/*methods | 2 | 40.0 |
Ultrasonography | 2 | 2.0 |
Kidney, Cystic/genetics | 2 | 40.0 |
Tuberous Sclerosis/genetics | 2 | 7.0 |
Base Pair Mismatch | 2 | 1.0 |
*Chromosome Mapping | 4 | 0.0 |
Adenoma, Oxyphilic/genetics/pathology | 2 | 100.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Genetic Markers/genetics | 2 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Carcinoma, Renal Cell/*metabolism | 3 | 13.0 |
Kidney Neoplasms/*metabolism | 4 | 14.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Kidney Neoplasms/diagnosis | 2 | 50.0 |
Kidney Neoplasms/diagnosis/genetics | 2 | 100.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Cell Compartmentation | 4 | 1.0 |
Cell Cycle Proteins/*metabolism | 4 | 1.0 |
Luminescent Proteins/genetics/metabolism | 2 | 1.0 |
RNA Polymerase II/metabolism | 4 | 3.0 |
Hippel-Lindau Disease/*surgery | 2 | 100.0 |
Neoplasms, Multiple Primary/diagnosis | 2 | 66.0 |
Chromosomes, Human, Pair 17 | 4 | 1.0 |
Acute Disease | 2 | 0.0 |
Haplotypes | 6 | 0.0 |
Carcinoma, Renal Cell/*complications | 2 | 100.0 |
Kidney Neoplasms/*complications | 2 | 66.0 |
Renal Dialysis | 2 | 0.0 |
Hippel-Lindau Disease/*genetics/radiography | 2 | 100.0 |
Genetic Counseling | 3 | 1.0 |
Hippel-Lindau Disease/diagnosis/epidemiology/*genetics | 2 | 100.0 |
Morbidity | 3 | 5.0 |
DNA Fingerprinting | 2 | 1.0 |
Chromosomes, Human, Pair 1/*genetics | 3 | 1.0 |
Cerebellar Neoplasms/diagnosis | 2 | 66.0 |
Hemangioma/diagnosis | 2 | 50.0 |
Retinal Neoplasms/diagnosis | 2 | 100.0 |
*Databases, Factual | 2 | 3.0 |
Diagnostic Imaging | 3 | 9.0 |
Gene Expression Regulation, Developmental | 4 | 0.0 |
Angiogenesis Inhibitors/*therapeutic use | 3 | 4.0 |
Transplantation, Heterologous | 3 | 0.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Endothelial Growth Factors/genetics | 2 | 2.0 |
Lymphokines/genetics | 2 | 2.0 |
Repressor Proteins/chemistry/genetics/metabolism | 2 | 11.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Proteins/*physiology | 3 | 1.0 |
Saccharomyces cerevisiae/metabolism | 3 | 2.0 |
DNA Mutational Analysis/methods | 4 | 1.0 |
Neoplasms/*genetics/metabolism | 2 | 6.0 |
Severity of Illness Index | 7 | 0.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
DNA Primers/genetics | 6 | 0.0 |
Patient Care Planning | 2 | 13.0 |
Visual Fields | 2 | 3.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Molecular Weight | 3 | 0.0 |
Codon/*genetics | 2 | 3.0 |
Cosmids/genetics | 2 | 3.0 |
*Disease Models, Animal | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Occupational Exposure | 2 | 2.0 |
United States | 3 | 0.0 |
Chromosome Aberrations/*genetics | 3 | 2.0 |
Chromosome Disorders | 8 | 2.0 |
Multiple Endocrine Neoplasia Type 1/*genetics | 2 | 1.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
*Microsatellite Repeats | 2 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
*Chromosomes, Human, Pair 8 | 3 | 1.0 |
Genes, p16 | 2 | 2.0 |
Mouth Neoplasms/*genetics | 4 | 8.0 |
Homozygote | 7 | 0.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Neovascularization, Pathologic/*genetics | 4 | 9.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 2 | 0.0 |
Alternative Splicing | 3 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Laryngectomy/*methods | 2 | 66.0 |
Vascular Endothelial Growth Factor A/genetics/metabolism | 2 | 8.0 |
Hemangioma/etiology | 3 | 75.0 |
Protein Structure, Secondary | 3 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Adrenal Gland Neoplasms/*complications/surgery | 2 | 66.0 |
Catecholamines/urine | 2 | 16.0 |
Hippel-Lindau Disease/*complications/diagnosis/genetics | 4 | 100.0 |
Pheochromocytoma/*complications/surgery | 2 | 100.0 |
Tissue Distribution | 5 | 0.0 |
Adenocarcinoma/genetics/pathology | 2 | 4.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Endolymphatic Sac/*pathology | 2 | 100.0 |
Hemangioblastoma/*complications/surgery | 2 | 100.0 |
Neoplasms, Multiple Primary | 2 | 13.0 |
Retinal Neoplasms/complications | 2 | 100.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
Apoptosis | 3 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Hippel-Lindau Disease/*genetics/physiopathology | 2 | 100.0 |
Microscopy, Electron | 2 | 0.0 |
Iron Chelating Agents/pharmacology | 2 | 8.0 |
Trichloroethylene/*adverse effects | 2 | 50.0 |
Endothelial Growth Factors/*genetics/metabolism | 2 | 4.0 |
*Gene Expression | 4 | 0.0 |
Lymphokines/*genetics/metabolism | 2 | 4.0 |
Hemangioma/genetics | 3 | 100.0 |
Nephrectomy/methods | 2 | 28.0 |
von Willebrand Factor/analysis | 2 | 0.0 |
Tumor Cells, Cultured/transplantation | 2 | 6.0 |
Cell Cycle | 3 | 0.0 |
S-Phase Kinase-Associated Proteins | 2 | 2.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Tumor Suppressor Proteins/genetics/*metabolism | 5 | 8.0 |
Ubiquitin-Protein Ligases/genetics/*metabolism | 5 | 26.0 |
Up-Regulation/genetics | 2 | 2.0 |
Surface Properties | 2 | 1.0 |
Cerebellar Neoplasms/genetics | 5 | 41.0 |
Kidney Neoplasms/genetics/pathology | 3 | 50.0 |
Open Reading Frames | 5 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
England/epidemiology | 2 | 3.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Great Britain/epidemiology | 3 | 2.0 |
Smoking | 2 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Cerebellum/metabolism | 2 | 4.0 |
Embryo/metabolism | 3 | 1.0 |
Genes, ras | 3 | 1.0 |
Protein p53/physiology | 2 | 2.0 |
Protein-Tyrosine-Phosphatase/genetics | 2 | 6.0 |
Hippel-Lindau Disease/genetics/metabolism | 2 | 100.0 |
Glucose/metabolism | 2 | 0.0 |
France/epidemiology | 2 | 1.0 |
Genes, Tumor Suppressor/*genetics/physiology | 2 | 50.0 |
Adenocarcinoma, Clear Cell/chemically induced/*genetics/pathology | 2 | 100.0 |
Kidney Neoplasms/chemically induced/*genetics/pathology | 2 | 66.0 |
Rats, Wistar | 3 | 0.0 |
Smoking/adverse effects | 2 | 0.0 |
Angiography | 2 | 4.0 |
Recurrence | 3 | 0.0 |
Hippel-Lindau Disease/genetics/pathology | 2 | 66.0 |
Tumor Suppressor Proteins/*physiology | 3 | 9.0 |
Postoperative Complications | 3 | 2.0 |
Carcinoma, Renal Cell/*enzymology/genetics/pathology | 2 | 66.0 |
Cell Membrane/enzymology | 2 | 0.0 |
Kidney Neoplasms/*enzymology/genetics/pathology | 2 | 50.0 |
Esophageal Neoplasms/*genetics | 2 | 2.0 |
Eye Neoplasms/genetics | 3 | 23.0 |
Cytosol/metabolism | 3 | 0.0 |
RNA Interference | 5 | 1.0 |
Carcinoma, Renal Cell/chemically induced/*genetics | 4 | 100.0 |
Diethylnitrosamine/analogs & derivatives | 2 | 100.0 |
Kidney Neoplasms/chemically induced/*genetics | 5 | 83.0 |
Tuberous Sclerosis/*genetics | 2 | 2.0 |
Chromosomes, Human, Pair 5 | 2 | 1.0 |
Carcinoma, Renal Cell/diagnosis/*genetics | 3 | 75.0 |
Kidney Neoplasms/diagnosis/*genetics | 3 | 50.0 |
Antigens, CD31/metabolism | 2 | 2.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Base Pair Mismatch/genetics | 2 | 4.0 |
Twins, Monozygotic | 2 | 2.0 |
Cell Transformation, Neoplastic/*genetics | 3 | 1.0 |
Muscle Proteins/genetics | 2 | 2.0 |
Chromosomes, Human, Pair 8 | 3 | 2.0 |
*Genetic Heterogeneity | 2 | 1.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Neoplasms, Multiple Primary/*genetics | 4 | 10.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
*Peptide Elongation Factors | 2 | 16.0 |
Head and Neck Neoplasms/*genetics | 3 | 4.0 |
Rats, Mutant Strains | 2 | 3.0 |
*Nephrectomy | 2 | 11.0 |
Decision Making | 2 | 2.0 |
Liver Neoplasms/secondary | 2 | 3.0 |
Half-Life | 2 | 0.0 |
Kidney Neoplasms/genetics/*metabolism | 3 | 25.0 |
Carcinoma, Renal Cell/*surgery | 3 | 100.0 |
Graft Survival | 2 | 0.0 |
Carcinoma, Renal Cell/*metabolism/pathology | 3 | 16.0 |
Epithelium/metabolism | 2 | 0.0 |
Kidney Neoplasms/*metabolism/pathology | 2 | 6.0 |
*DNA Mutational Analysis | 3 | 1.0 |
Carcinoma, Renal Cell/classification/*genetics/pathology | 2 | 100.0 |
Kidney Neoplasms/classification/*genetics/pathology | 2 | 66.0 |
Enzyme-Linked Immunosorbent Assay | 4 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Tumor Suppressor Proteins/*genetics/metabolism | 4 | 11.0 |
Ubiquitin-Protein Ligases/*genetics/metabolism | 4 | 36.0 |
Adenocarcinoma, Follicular/*genetics/mortality | 2 | 100.0 |
Thyroid Neoplasms/*genetics/mortality | 2 | 40.0 |
DNA/genetics | 4 | 0.0 |
Adenoma/*genetics/pathology | 3 | 11.0 |
Caenorhabditis elegans | 4 | 4.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Cell Division/physiology | 3 | 0.0 |
Kidney Neoplasms/*surgery | 2 | 100.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Anoxia | 2 | 2.0 |
Proportional Hazards Models | 2 | 0.0 |
*CpG Islands | 2 | 2.0 |
Embryonic and Fetal Development/*genetics | 2 | 2.0 |
*Nerve Growth Factors | 2 | 1.0 |
Nerve Tissue Proteins/*genetics | 2 | 0.0 |
Repressor Proteins/*genetics | 4 | 1.0 |
DNA, Neoplasm/*analysis/genetics | 2 | 13.0 |
Genes, p53/*genetics | 2 | 0.0 |
Kidney | 2 | 0.0 |
DNA/*analysis | 3 | 1.0 |
Hippel-Lindau Disease/*diagnosis/genetics | 4 | 100.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Carcinoma, Renal Cell/epidemiology/genetics | 2 | 100.0 |
Cerebellar Neoplasms/etiology/*genetics | 2 | 100.0 |
Hemangioblastoma/etiology/*genetics | 2 | 100.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Liver/metabolism | 2 | 0.0 |
Proteins/isolation & purification/*metabolism | 2 | 6.0 |
Life Tables | 2 | 1.0 |
Brain Neoplasms/genetics | 2 | 11.0 |
Radionuclide Imaging | 2 | 14.0 |
Proteins/metabolism | 2 | 0.0 |
Abnormalities, Multiple/*genetics | 2 | 0.0 |
Pheochromocytoma/complications/*genetics | 3 | 75.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Europe/epidemiology | 2 | 2.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Internet | 2 | 2.0 |
Carrier Proteins/biosynthesis/genetics/*metabolism | 2 | 25.0 |
Hemangioblastoma | 2 | 100.0 |
Carcinoma, Renal Cell/metabolism/*pathology | 2 | 28.0 |
Kidney Neoplasms/metabolism/*pathology | 2 | 11.0 |
*Proto-Oncogenes | 2 | 0.0 |
Transcription Factors/chemistry/*genetics/metabolism | 2 | 4.0 |
Genes, APC | 2 | 2.0 |
Colorectal Neoplasms/*genetics/pathology | 3 | 3.0 |
Europe | 2 | 0.0 |
*Heterozygote | 2 | 0.0 |
Codon | 2 | 0.0 |
Multiple Endocrine Neoplasia Type 2b/genetics | 2 | 16.0 |
Hemangioblastoma/pathology | 2 | 66.0 |
Hippel-Lindau Disease/*pathology | 4 | 80.0 |
Endothelial Growth Factors/genetics/metabolism | 2 | 4.0 |
Nuclear Proteins/*genetics | 3 | 0.0 |
Thyroid Neoplasms/genetics | 2 | 7.0 |
Transcription Factors/*physiology | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Carcinoma, Renal Cell | 3 | 27.0 |
Fatal Outcome | 2 | 0.0 |
Adrenal Gland Neoplasms/complications/*genetics | 2 | 66.0 |
DNA, Complementary | 2 | 0.0 |
Nasopharyngeal Neoplasms/*genetics | 2 | 9.0 |
*Founder Effect | 2 | 1.0 |
Germany | 2 | 0.0 |
Kidney Neoplasms | 3 | 16.0 |
DNA Probes | 6 | 0.0 |
Carcinoma, Papillary/genetics | 3 | 20.0 |
Germ Cells | 2 | 10.0 |
Molecular Structure | 2 | 0.0 |
Ca(2+)-Transporting ATPase/*genetics | 3 | 11.0 |
*Magnetic Resonance Imaging | 4 | 2.0 |
*Linkage (Genetics) | 3 | 0.0 |
Models, Chemical | 2 | 0.0 |
Hemangioblastoma/*diagnosis | 2 | 100.0 |
Preoperative Care | 2 | 1.0 |
Tumor Suppressor Proteins/genetics/*physiology | 2 | 14.0 |
Ubiquitin-Protein Ligases/genetics/*physiology | 2 | 100.0 |
Neoplastic Syndromes, Hereditary/*genetics | 3 | 7.0 |
Retinal Diseases/genetics | 2 | 18.0 |
Cytoplasm/*metabolism | 3 | 2.0 |
China | 3 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
*Proteasome Endopeptidase Complex | 2 | 3.0 |
*Deoxyribonucleases, Type II Site-Specific | 2 | 3.0 |
*Phenotype | 2 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Paraganglioma/*genetics | 3 | 20.0 |
DNA, Satellite/genetics | 2 | 1.0 |
*Polymorphism, Genetic | 3 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Carcinoma, Renal Cell/complications/*genetics | 2 | 100.0 |
Kidney Neoplasms/complications/*genetics | 2 | 28.0 |
Cosmids | 2 | 0.0 |
Chromosome Banding | 3 | 0.0 |
Spain | 2 | 0.0 |
Visual Acuity/*physiology | 2 | 25.0 |
Lod Score | 6 | 0.0 |
Nuclear Proteins/*physiology | 2 | 1.0 |
Ubiquitin-Protein Ligases/*physiology | 2 | 28.0 |
Fibronectins/metabolism | 2 | 1.0 |
Vascular Endothelial Growth Factor A/metabolism | 2 | 1.0 |
Chromosome Fragile Sites | 2 | 1.0 |
*Chromosome Fragility | 2 | 1.0 |
Angiomatosis/*genetics | 7 | 100.0 |
*Diagnostic Imaging | 2 | 25.0 |
Anoxia/*metabolism | 2 | 3.0 |
Tumor Suppressor Proteins/*metabolism | 6 | 6.0 |
Ubiquitin-Protein Ligases/*metabolism | 4 | 16.0 |
Angiomatosis/*diagnosis | 2 | 100.0 |
Gadolinium/diagnostic use | 2 | 12.0 |
Introns/genetics | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Hyperplasia | 2 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Trans-Activators/genetics | 2 | 0.0 |
Carcinoma, Renal Cell/*genetics/*metabolism/pathology | 2 | 100.0 |
Hippel-Lindau Disease | 2 | 66.0 |
Ligases/deficiency/*genetics | 3 | 60.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Hemangioblastoma/*etiology/physiopathology/*surgery | 3 | 100.0 |
Hippel-Lindau Disease/*complications/pathology/physiopathology | 2 | 100.0 |
*Outcome Assessment (Health Care) | 3 | 6.0 |
Recovery of Function/physiology | 3 | 27.0 |
Spinal Cord Neoplasms/*etiology/physiopathology/*surgery | 2 | 100.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 2 | 7.0 |
Lung Neoplasms/*genetics/pathology | 2 | 2.0 |
Arginine | 2 | 2.0 |
Leucine | 2 | 4.0 |
